Among the drugs targeting immune checkpoints, nivolumab and pembrolizumab were used to target programmed cell death protein 1 (PD-1) in GBM, while ipilimumab was used against the cytotoxic T lymphocyte antigen 4 (CTLA4) [56]. Here, PDCD1 is linked to glioblastoma.